Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Alzheimer's Disease
100%
Treatment Effect
100%
Oscillation
100%
Alzheime's Disease
100%
Alzheimer's Disease Dementia
100%
Ongoing EEG
100%
Electroencephalography
60%
Dementia Patients
60%
Mild Cognitive Impairment
60%
Cognitive Dementia
40%
Acetylcholinesterase Inhibitors (AChEI)
40%
P300
20%
Theta Band
20%
Older Persons
20%
Disease-modifying Therapy
20%
Peak Amplitude
20%
Oddball Paradigm
20%
Amyloid beta
20%
Group Level
20%
Visual Stimuli
20%
Multicentric
20%
Peak Latency
20%
Electrophysiology
20%
Phase Locking
20%
Global Brain
20%
Professional Interest
20%
Alzheimer's Association
20%
Expert Panel
20%
Human Cognitive Functions
20%
Randomized Controlled Clinical Trial
20%
Aducanumab
20%
Placebo-controlled Clinical Trial
20%
Symptomatic Drugs
20%
Tauopathy
20%
Spectral Coherence
20%
Clinical Efficacy
20%
Neurodegenerative Disorders
20%
Cognitive Impairment Diseases
20%
INIS
nervous system diseases
100%
potentials
100%
oscillations
100%
patients
30%
drugs
30%
brain
15%
erbium phosphides
15%
diseases
15%
levels
7%
accumulation
7%
humans
7%
stimuli
7%
peaks
7%
validation
7%
amplitudes
7%
clinical trials
7%
biological markers
7%
electrodes
7%
panels
7%
proteins
7%
reserves
7%
electrophysiology
7%
phase oscillations
7%
Neuroscience
Electroencephalography
100%
Alzheimer's Disease
100%
Mild Cognitive Impairment
42%
Acetylcholinesterase Inhibitor
28%
Cognitive Function
14%
Neurodegenerative Disorder
14%
Oddball Paradigm
14%
Aducanumab
14%
Placebo
14%
Electrophysiology
14%
Tauopathy
14%
Biological Marker
14%
Amyloid Beta
14%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Mild Cognitive Impairment
42%
Diseases
42%
Cholinesterase Inhibitor
28%
Biological Marker
14%
Placebo
14%
Cross-Validation
14%
Aducanumab
14%
Amyloid Protein
14%
Tauopathy
14%
Controlled Clinical Trial
14%